Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Xenon (XENE – Research Report) today and set a price target of $53.00.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...